{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:20:53Z","timestamp":1773357653831,"version":"3.50.1"},"reference-count":505,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1055\/a-1589-7568","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T18:38:34Z","timestamp":1642531114000},"page":"e56-e130","source":"Crossref","is-referenced-by-count":6,"title":["S3-Leitlinie: Diagnostik und Therapie des hepatozellul\u00e4ren Karzinoms"],"prefix":"10.1055","volume":"60","author":[{"given":"Voesch","family":"Sabrina","sequence":"additional","affiliation":[{"name":"Medizinische Klinik I, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bitzer","family":"Michael","sequence":"additional","affiliation":[{"name":"Medizinische Klinik I, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"J\u00f6rg","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Gastroenterologie, Hepatologie und Endokrinologie, Stuttgart"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartenstein","family":"Peter","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Nuklearmedizin, LMU Klinikum, M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bechstein","family":"Wolf","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Allgemein-, Viszeral-, Transplantations- und Thoraxchirurgie, Universit\u00e4tsklinikum Frankfurt, Frankfurt am Main"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bl\u00f6dt","family":"Susanne","sequence":"additional","affiliation":[{"name":"AWMF-Gesch\u00e4ftsstelle, Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brunner","family":"Thomas","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Strahlentherapie, Universit\u00e4tsklinikum Magdeburg A. \u00f6. R., Magdeburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dombrowski","family":"Frank","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pathologie, Universit\u00e4tsmedizin Greifswald, Greifswald"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evert","family":"Matthias","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pathologie, Regensburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Follmann","family":"Markus","sequence":"additional","affiliation":[{"name":"Office des Leitlinienprogrammes Onkologie, c\/o Deutsche Krebsgesellschaft e.V. Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"La Foug\u00e8re","family":"Christian","sequence":"additional","affiliation":[{"name":"Nuklearmedizin und Klinische Molekulare Bildgebung, T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freudenberger","family":"Paul","sequence":"additional","affiliation":[{"name":"Clinical Guideline Services GmbH, Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geier","family":"Andreas","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gkika","family":"Eleni","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Strahlenheilkunde, Department f\u00fcr Radiologische Diagnostik und Therapie, Universit\u00e4tsklinikum Freiburg, Freiburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6tz","family":"Martin","sequence":"additional","affiliation":[{"name":"Kliniken B\u00f6blingen, B\u00f6blingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hammes","family":"Elke","sequence":"additional","affiliation":[{"name":"Lebertransplantierte Deutschland e. V., Ansbach"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmberger","family":"Thomas","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Radiologie, Neuroradiologie und minimal-invasive Therapie, M\u00fcnchen Klinik Bogenhausen, M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoffmann","family":"Ralf-Thorsten","sequence":"additional","affiliation":[{"name":"Institut und Poliklinik f\u00fcr Diagnostische und Interventionelle Radiologie, Dresden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hofmann","family":"Wolf-Peter","sequence":"additional","affiliation":[{"name":"Gastroenterologie am Bayerischen Platz, medizinisches Versorgungszentrum, Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huppert","family":"Peter","sequence":"additional","affiliation":[{"name":"Radiologisches Zentrum, Max Grundig Klinik, B\u00fchl"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kautz","family":"Achim","sequence":"additional","affiliation":[{"name":"Deutsche Leberhilfe e.V., K\u00f6ln"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kn\u00f6tgen","family":"Gabi","sequence":"additional","affiliation":[{"name":"Konferenz onkologischer Kranken- und Kinderkrankenpflege, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00f6rber","family":"J\u00fcrgen","sequence":"additional","affiliation":[{"name":"Klinik Nahetal, Fachklinik f\u00fcr onkologische Rehabilitation und Anschlussrehabilitation, (AHB), Bad Kreuznach"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krug","family":"David","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Strahlentherapie, Universit\u00e4tsklinikum Schleswig-Holstein, Kiel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lammert","family":"Frank","sequence":"additional","affiliation":[{"name":"Medizinische Hochschule Hannover, Hannover"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Hauke","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Allgemein-, Viszeral und Transplantationschirurgie, Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz, Mainz"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Langer","family":"Thomas","sequence":"additional","affiliation":[{"name":"Office des Leitlinienprogrammes Onkologie, c\/o Deutsche Krebsgesellschaft e.V. Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenz","family":"Philipp","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum M\u00fcnster, Zentrale Einrichtung Palliativmedizin, M\u00fcnster"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahnken","family":"Andreas","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Diagnostische und Interventionelle Radiologie, Universit\u00e4tsklinikum Gie\u00dfen und Marburg GmbH, Marburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meining","family":"Alexander","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II des Universit\u00e4tsklinikums W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micke","family":"Oliver","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Strahlentherapie und Radioonkologie, Franziskus Hospital Bielefeld, Bielefeld"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadalin","family":"Silvio","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinik f\u00fcr Allgemein-, Viszeral- und Transplantationschirurgie, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen","family":"Huu Phuc","sequence":"additional","affiliation":[{"name":"Humangenetik, Ruhr-Universit\u00e4t, Bochum"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ockenga","family":"Johann","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II, Klinikum Bremen-Mitte, Bremen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oldhafer","family":"Karl-J\u00fcrgen","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Leber-, Gallenwegs- und Pankreaschirurgie, Semmelweis Universit\u00e4t, Asklepios Campus Hamburg, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paprottka","family":"Philipp","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr interventionelle Radiologie, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paradies","family":"Kerstin","sequence":"additional","affiliation":[{"name":"Konferenz onkologischer Kranken- und Kinderkrankenpflege, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pereira","family":"Philippe","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Radiologie, Minimal-invasive Therapien und Nuklearmedizin, Klinikum am Gesundbrunnen, SLK-Kliniken Heilbronn GmbH, Heilbronn"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Persigehl","family":"Thorsten","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Diagnostische und Interventionelle Radiologie, Universit\u00e4tsklinikum K\u00f6ln, K\u00f6ln"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Plauth","family":"Mathias","sequence":"additional","affiliation":[{"name":"St\u00e4dtisches Klinikum Dessau, Dessau"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Plentz","family":"Ruben","sequence":"additional","affiliation":[{"name":"Klinikum Bremen-Nord, Innere Medizin, Bremen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pohl","family":"J\u00fcrgen","sequence":"additional","affiliation":[{"name":"Interventionelles Endoskopiezentrum und Schwerpunkt Gastrointestinale Onkologie, Asklepios Klinik Altona, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riemer","family":"Jutta","sequence":"additional","affiliation":[{"name":"Lebertransplantierte Deutschland e. V., Bretzfeld"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reimer","family":"Peter","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr diagnostische und interventionelle Radiologie, St\u00e4dtisches Klinikum Karlsruhe gGmbH, Karlsruhe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ringwald","family":"Johanna","sequence":"additional","affiliation":[{"name":"Psychosomatische Medizin und Psychotherapie, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritterbusch","family":"Ulrike","sequence":"additional","affiliation":[{"name":"Hospizarbeit am Universit\u00e4tsklinikum Essen, Essen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roeb","family":"Elke","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II, Universit\u00e4tsklinikum Gie\u00dfen und Marburg GmbH, Gie\u00dfen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Schellhaas","family":"Barbara","sequence":"additional","affiliation":[{"name":"Medizinische Klinik I, Friedrich-Alexander Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Schirmacher","family":"Peter","sequence":"additional","affiliation":[{"name":"Pathologisches Institut, Universit\u00e4tsklinikum Heidelberg, Heidelberg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Schmid","family":"Irene","sequence":"additional","affiliation":[{"name":"Zentrum P\u00e4diatrische H\u00e4matologie und Onkologie, Dr. von Haunersches Kinderspital, Klinikum der Universit\u00e4t M\u00fcnchen, M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Schuler","family":"Andreas","sequence":"additional","affiliation":[{"name":"Medizinische Klinik, Alb Fils Kliniken GmbH, G\u00f6ppingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"von Schweinitz","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Dietrich (SRH Wilhelm L\u00f6he Hochschule, F\u00fcrth"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seehofer","family":"Daniel","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Viszeral-, Transplantations-, Thorax- und Gef\u00e4\u00dfchirurgie, Universit\u00e4tsklinikum Leipzig, Leipzig"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinn","family":"Marianne","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II, Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stein","family":"Alexander","sequence":"additional","affiliation":[{"name":"H\u00e4matologisch-Onkologischen Praxis Eppendorf, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stengel","family":"Andreas","sequence":"additional","affiliation":[{"name":"Psychosomatische Medizin und Psychotherapie, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steubesand","family":"Nadine","sequence":"additional","affiliation":[{"name":"Clinical Guideline Services GmbH, Kiel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stoll","family":"Christian","sequence":"additional","affiliation":[{"name":"Klinik Herzogh\u00f6he Bayreuth, Bayreuth"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tannapfel","family":"Andrea","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pathologie der Ruhr-Universit\u00e4t Bochum am Berufsgenossenschaftlichen Universit\u00e4tsklinikum Bergmannsheil, Bochum"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taubert","family":"Anne","sequence":"additional","affiliation":[{"name":"Kliniksozialdienst, Universit\u00e4tsklinikum Heidelberg, Bochum"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trojan","family":"J\u00f6rg","sequence":"additional","affiliation":[{"name":"Medizinische Klinik I, Universit\u00e4tsklinikum Frankfurt, Frankfurt am Main"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"van Thiel","family":"Ingo","sequence":"additional","affiliation":[{"name":"Deutsche Leberhilfe e.V., K\u00f6ln"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tholen","family":"Reina","sequence":"additional","affiliation":[{"name":"Deutscher Verband f\u00fcr Physiotherapie e. V., K\u00f6ln"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vogel","family":"Arndt","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, Hepatologie, Endokrinologie der Medizinischen Hochschule Hannover, Hannover"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vogl","family":"Thomas","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Frankfurt, Institut f\u00fcr Diagnostische und Interventionelle Radiologie, Frankfurt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vorwerk","family":"Hilke","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Strahlentherapie, Universit\u00e4tsklinikum Gie\u00dfen und Marburg GmbH, Marburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wacker","family":"Frank","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Diagnostische und Interventionelle Radiologie der Medizinischen Hochschule Hannover, Hannover"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waidmann","family":"Oliver","sequence":"additional","affiliation":[{"name":"Medizinische Klinik I, Universit\u00e4tsklinikum Frankfurt, Frankfurt am Main"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wedemeyer","family":"Heiner","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, Hepatologie und Endokrinologie Medizinische Hochschule Hannover, Hannover"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wege","family":"Henning","sequence":"additional","affiliation":[{"name":"I. Medizinische Klinik und Poliklinik, Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wildner","family":"Dane","sequence":"additional","affiliation":[{"name":"Innere Medizin, Krankenh\u00e4user N\u00fcrnberger Land GmbH, Lauf an der Pegnitz"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wittekind","family":"Christian","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Leipzig, Leipzig"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W\u00f6rns","family":"Marcus-Alexander","sequence":"additional","affiliation":[{"name":"I. Medizinische Klinik und Poliklinik, Universit\u00e4tsklinikum Mainz, Mainz"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galle","family":"Peter","sequence":"additional","affiliation":[{"name":"I. Medizinische Klinik und Poliklinik, Universit\u00e4tsklinikum Mainz, Mainz"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malek","family":"Nisar","sequence":"additional","affiliation":[{"name":"Medizinische Klinik I, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"ref3","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"J Bruix","year":"2011","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.21176","article-title":"The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients","volume":"43","author":"A Sangiovanni","year":"2006","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","article-title":"Incidence and predictors of hepatocellular carcinoma in\u00a0patients with cirrhosis","volume":"5","author":"G N Ioannou","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents","volume":"71","author":"F Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease","volume":"155","author":"F Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.mayocpiqo.2019.04.005","article-title":"A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk","volume":"3","author":"C T Frenette","year":"2019","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.bpg.2013.08.021","article-title":"Cost-effectiveness of liver cancer screening","volume":"27","author":"A Cucchetti","year":"2013","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jvh.12727","article-title":"Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score","volume":"24","author":"W P Brouwer","year":"2017","journal-title":"J Viral Hepat"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"G Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review","volume":"53","author":"G V Papatheodoridis","year":"2010","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"M F Yuen","year":"2009","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"H I Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"V W Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2019.12.005","article-title":"Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B","volume":"72","author":"T C Yip","year":"2020","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"J A Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease","volume":"14","author":"S Mittal","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease","volume":"156","author":"L Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"ref25","first-page":"668","article-title":"[S2k Guideline non-alcoholic fatty liver disease]","volume":"53","author":"E Roeb","year":"2015","journal-title":"Z Gastroenterol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/a-0784-8827","article-title":"Nonalcoholic steatohepatitis (NASH) \u2013 current treatment recommendations and future developments","volume":"57","author":"E Roeb","year":"2019","journal-title":"Z Gastroenterol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"P Angulo","year":"2007","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/MCG.0000000000000581","article-title":"Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid","volume":"51","author":"S Tanwar","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents","volume":"153","author":"F Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/hep.22870","article-title":"Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography","volume":"49","author":"R Masuzaki","year":"2009","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"H B El-Serag","year":"2016","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores","volume":"157","author":"G N Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"M Omata","year":"2017","journal-title":"Hepatol Int"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2017.10.006","article-title":"Should we undertake surveillance for HCC in patients with NAFLD?","volume":"68","author":"R Younes","year":"2018","journal-title":"J Hepatol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2147\/CLEP.S144368","article-title":"Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes","volume":"9","author":"J C Simeone","year":"2017","journal-title":"Clin Epidemiol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"N Fujiwara","year":"2018","journal-title":"J Hepatol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population","volume":"72","author":"H Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0168-8278(20)30665-6","article-title":"Primary liver cancer in acute hepatic porphyria: a national cohort study","volume":"73","author":"M Lissing","year":"2020","journal-title":"Journal of Hepatology"},{"issue":"S 01","key":"ref39","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1007\/BF02072092","article-title":"Glycogen storage disease I and hepatocellular tumours","volume":"152","author":"L Bianchi","year":"1993","journal-title":"Eur J Pediatr"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2005.08.004","article-title":"Increased incidence of cancer in adult Gaucher disease in Western Europe","volume":"36","author":"M de Fost","year":"2006","journal-title":"Blood Cells Mol Dis"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10545-014-9683-x","article-title":"Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function","volume":"37","author":"D C Bartlett","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis","volume":"36","author":"E Raffetti","year":"2016","journal-title":"Liver Int"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"G V Papatheodoridis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(09)70241-4","article-title":"Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009","volume":"10","author":"D Poon","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group","volume":"336","author":"M H Chang","year":"1997","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S2468-1253(19)30042-1","article-title":"Hepatitis B virus infection in children and adolescents","volume":"4","author":"G Indolfi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jnci\/dji040","article-title":"Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan","volume":"97","author":"M Inoue","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/CEJ.0000000000000252","article-title":"Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies","volume":"26","author":"F Bravi","year":"2017","journal-title":"Eur J Cancer Prev"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3945\/ajcn.115.116095","article-title":"The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition","volume":"102","author":"K Aleksandrova","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.gastro.2014.10.005","article-title":"Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort","volume":"148","author":"V W Setiawan","year":"2015","journal-title":"Gastroenterology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/liv.12304","article-title":"Impact of coffee on liver diseases: a systematic review","volume":"34","author":"S Saab","year":"2014","journal-title":"Liver Int"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"421","DOI":"10.15403\/jgld-805","article-title":"Inverse Association of Coffee with Liver Cancer Development: An Updated Systematic Review and Meta-analysis","volume":"29","author":"A Bhurwal","year":"2020","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"e013739","DOI":"10.1136\/bmjopen-2016-013739","article-title":"Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis","volume":"7","author":"O J Kennedy","year":"2017","journal-title":"BMJ Open"},{"key":"ref54","first-page":"Cd005004","article-title":"Green tea (Camellia sinensis) for the prevention of cancer","volume":"3","author":"T Filippini","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.cgh.2013.07.034","article-title":"Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"11","author":"S Singh","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1111\/liv.13872","article-title":"Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes","volume":"38","author":"C H Tseng","year":"2018","journal-title":"Liver Int"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.aohep.2019.10.005","article-title":"Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review","volume":"19","author":"V Cunha","year":"2020","journal-title":"Ann Hepatol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1177\/1060028013503108","article-title":"Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C","volume":"47","author":"K Harris","year":"2013","journal-title":"Ann Pharmacother"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"S E Inzucchi","year":"2014","journal-title":"Jama"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.27199","article-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes","volume":"60","author":"X Zhang","year":"2014","journal-title":"Hepatology"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2016.04.031","article-title":"Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study","volume":"65","author":"H Vandenbulcke","year":"2016","journal-title":"J Hepatol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"M S Ascha","year":"2010","journal-title":"Hepatology"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical Practice Guidelines: Management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.amjsurg.2019.05.016","article-title":"Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3\u202fcm \u2013 A retrospective cohort study","volume":"219","author":"Z Y Wang","year":"2020","journal-title":"Am J Surg"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/cid\/ciz860","article-title":"Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy","volume":"71","author":"J W Jang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/liv.12805","article-title":"A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib","volume":"35","author":"Y Yang","year":"2015","journal-title":"Liver Int"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"G Cabibbo","year":"2019","journal-title":"J Hepatol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/hep.30988","article-title":"Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West","volume":"71","author":"H Dang","year":"2020","journal-title":"Hepatology"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"B H Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/j.1572-0241.2007.01395.x","article-title":"Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate\/advanced cirrhosis?","volume":"102","author":"F Trevisani","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/j.1572-0241.2007.01395.x","article-title":"Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate\/advanced cirrhosis?","volume":"102","author":"F Trevisani","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/apt.12370","article-title":"Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography \u2013 a randomised study","volume":"38","author":"C Pocha","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep.24545","article-title":"Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities","volume":"54","author":"J C Trinchet","year":"2011","journal-title":"Hepatology"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A\u00a0Meta-analysis","volume":"154","author":"K Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/MEG.0000000000001226","article-title":"Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy","volume":"30","author":"B G Song","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"e1001624","DOI":"10.1371\/journal.pmed.1001624","article-title":"Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis","volume":"11","author":"A G Singal","year":"2014","journal-title":"PLoS Med"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review","volume":"158","author":"R Loomba","year":"2020","journal-title":"Gastroenterology"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41395-018-0207-4","article-title":"Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis","volume":"113","author":"J L Petrick","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non-invasive assessment of hepatic fibrosis","volume":"69","author":"R Loomba","year":"2020","journal-title":"Gut"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"S Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"R K Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"R S Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"D C Rockey","year":"2009","journal-title":"Hepatology"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1136\/gut.2008.149062","article-title":"Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis","volume":"57","author":"M A Silva","year":"2008","journal-title":"Gut"},{"issue":"S 02","key":"ref85","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1002\/lt.22374","article-title":"Is tumor biopsy necessary?","volume":"17","author":"B M\u00fcllhaupt","year":"2011","journal-title":"Liver Transpl"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2014.04.046","article-title":"Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC","volume":"610","author":"D Fuks","year":"2014","journal-title":"J Hepatol"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.1840220341","article-title":"Terminology of nodular hepatocellular lesions","volume":"22","year":"1995","journal-title":"Hepatology"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.22709","article-title":"Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia","volume":"49","year":"2009","journal-title":"Hepatology"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/his.13520","article-title":"Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"73","author":"A D Burt","year":"2018","journal-title":"Histopathology"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E","article-title":"Primary carcinoma of the liver. A study of 100 cases among 48900 necropsies","volume":"7","author":"H A Edmondson","year":"1954","journal-title":"Cancer"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/1097-0142(19950815)76:4<579::AID-CNCR2820760407>3.0.CO;2-D","article-title":"Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma","volume":"76","author":"U C Nzeako","year":"1995","journal-title":"Cancer"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/hep.21531","article-title":"Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis","volume":"45","author":"L Di Tommaso","year":"2007","journal-title":"Hepatology"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jhep.2008.11.014","article-title":"The application of markers (HSP70 GPC3 and GS) in\u00a0liver biopsies is useful for detection of hepatocellular carcinoma","volume":"50","author":"L Di Tommaso","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1148\/radiol.14140690","article-title":"Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis","volume":"275","author":"Y J Lee","year":"2015","journal-title":"Radiology"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2463\/mrms.2014-0149","article-title":"Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma","volume":"15","author":"N Chen","year":"2016","journal-title":"Magn Reson Med Sci"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/apt.12166","article-title":"Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study","volume":"37","author":"A Granito","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/jmri.22588","article-title":"Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging","volume":"34","author":"H Haradome","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s00535-012-0571-6","article-title":"Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT","volume":"47","author":"T Inoue","year":"2012","journal-title":"J Gastroenterol"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"e111935","DOI":"10.1371\/journal.pone.0111935","article-title":"Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?","volume":"9","author":"B Maiwald","year":"2014","journal-title":"PLoS One"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/liv.12550","article-title":"Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT","volume":"34","author":"V Y Park","year":"2014","journal-title":"Liver Int"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/RLI.0b013e3181c5faf7","article-title":"Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging","volume":"45","author":"H Y Sun","year":"2010","journal-title":"Invest Radiol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00535-015-1097-5","article-title":"Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study","volume":"51","author":"M Tsurusaki","year":"2016","journal-title":"J Gastroenterol"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.1840380430","article-title":"MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation","volume":"38","author":"M Burrel","year":"2003","journal-title":"Hepatology"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00330-012-2691-z","article-title":"Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging","volume":"23","author":"M Di Martino","year":"2013","journal-title":"Eur Radiol"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00259-015-3241-0","article-title":"Diagnostic value of combining (1)(1)C-choline and (1)(8)F-FDG PET\/CT in hepatocellular carcinoma","volume":"43","author":"M A Castilla-Lievre","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref107","first-page":"3569","article-title":"Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET\/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT","volume":"17","author":"C Chotipanich","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jhep.2015.11.033","article-title":"Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation","volume":"64","author":"G Hong","year":"2016","journal-title":"J Hepatol"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1097\/RLU.0000000000001545","article-title":"Predictive Value of 18F-FDG PET\/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation","volume":"42","author":"C Y Lin","year":"2017","journal-title":"Clin Nucl Med"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2010.07.025","article-title":"Optimization of imaging diagnosis of 1\u20132 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization","volume":"54","author":"K Khalili","year":"2011","journal-title":"J Hepatol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"205","DOI":"10.15403\/jgld.2014.1121.252.chu","article-title":"Contrast-Enhanced Ultrasound: a Simple and Effective Tool in Defining a Rapid Diagnostic Work-up for Small Nodules Detected in Cirrhotic Patients during Surveillance","volume":"25","author":"A Giorgio","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/MEG.0000000000000916","article-title":"Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS","volume":"29","author":"B Schellhaas","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.27304","article-title":"LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions","volume":"61","author":"D G Mitchell","year":"2015","journal-title":"Hepatology"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"J M Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1477-2574.2012.00617.x","article-title":"Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system","volume":"15","author":"A C Chan","year":"2013","journal-title":"HPB (Oxford)"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-8278(99)80173-1","article-title":"A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d\u2019Etude et de Traitement du Carcinome Hepatocellulaire","volume":"31","author":"S Chevret","year":"1999","journal-title":"J Hepatol"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach \u2013  the ALBI grade","volume":"33","author":"P J Johnson","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"S 01","key":"ref118","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000173428","article-title":"Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score","volume":"75","author":"S Kitai","year":"2008","journal-title":"Oncology"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/cncr.10384","article-title":"Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients","volume":"94","author":"T W Leung","year":"2002","journal-title":"Cancer"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.20636","article-title":"Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort","volume":"41","author":"J A Marrero","year":"2005","journal-title":"Hepatology"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"D J Pinato","year":"2017","journal-title":"J Hepatol"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.transproceed.2009.03.054","article-title":"Validation of the BCLC prognostic system in surgical hepatocellular cancer patients","volume":"41","author":"A Vitale","year":"2009","journal-title":"Transplant Proc"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","article-title":"Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma","volume":"146","author":"T Yau","year":"2014","journal-title":"Gastroenterology"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.cgh.2016.10.036","article-title":"Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy","volume":"15","author":"J H Sohn","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"97428","DOI":"10.18632\/oncotarget.22134","article-title":"Comparison between liver resection and liver transplantation on outcomes in patients with solitary hepatocellular carcinoma meeting UNOS criteria: a population-based study of the SEER database","volume":"8","author":"A Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s11605-018-3690-4","article-title":"Liver Transplantation and Liver Resection for Cirrhotic Patients with Hepatocellular Carcinoma: Comparison of Long-Term Survivals","volume":"22","author":"F Krenzien","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/SLA.0b013e3181bd582b","article-title":"Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation","volume":"250","author":"D Cherqui","year":"2009","journal-title":"Ann Surg"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/bjs.7393","article-title":"Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma","volume":"98","author":"S Eguchi","year":"2011","journal-title":"Br J Surg"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/hep.28643","article-title":"The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study","volume":"64","author":"G Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/lt.24963","article-title":"Pro (With Caution): Extended oncologic indications in liver transplantation","volume":"24","author":"V Mazzaferro","year":"2018","journal-title":"Liver Transpl"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"V Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/SLA.0000000000002381","article-title":"Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium","volume":"266","author":"V G Agopian","year":"2017","journal-title":"Ann Surg"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/lt.25731","article-title":"Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma","volume":"26","author":"J von Felden","year":"2020","journal-title":"Liver Transpl"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"F Y Yao","year":"2001","journal-title":"Hepatology"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a\u00a0retrospective, exploratory analysis","volume":"10","author":"V Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/hep.30570","article-title":"Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol","volume":"70","author":"J Sinha","year":"2019","journal-title":"Hepatology"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3390\/cancers12020452","article-title":"Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort","volume":"12","author":"Q Lai","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cgh.2017.11.037","article-title":"Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A\u00a0Multicenter Study","volume":"16","author":"N Mehta","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/lt.20837","article-title":"Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma","volume":"12","author":"G Otto","year":"2006","journal-title":"Liver Transpl"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jamcollsurg.2018.03.025","article-title":"Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients","volume":"226","author":"S Di Sandro","year":"2018","journal-title":"J Am Coll Surg"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/hep.28339","article-title":"Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection","volume":"63","author":"J Ferrer-F\u00e0brega","year":"2016","journal-title":"Hepatology"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/jso.23916","article-title":"Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation","volume":"111","author":"O Scatton","year":"2015","journal-title":"J Surg Oncol"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.29468","article-title":"Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis","volume":"67","author":"R J de Haas","year":"2018","journal-title":"Hepatology"},{"key":"ref145","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/SLA.0000000000001442","article-title":"Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes?","volume":"264","author":"P Bhangui","year":"2016","journal-title":"Ann Surg"},{"issue":"S 01","key":"ref146","first-page":"478","article-title":"Is there a place for liver grafting for malignancy?","volume":"20","author":"R Pichlmayr","year":"1988","journal-title":"Transplant Proc"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/lt.20128","article-title":"Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis","volume":"10","author":"S Roayaie","year":"2004","journal-title":"Liver Transpl"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/lt.20140","article-title":"Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome","volume":"10","author":"K Shetty","year":"2004","journal-title":"Liver Transpl"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/lt.25056","article-title":"Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma","volume":"24","author":"H W Lee","year":"2018","journal-title":"Liver Transpl"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/lt.23652","article-title":"Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma","volume":"19","author":"K Berry","year":"2013","journal-title":"Liver Transpl"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-6143.2009.02750.x","article-title":"Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor","volume":"10","author":"E Vibert","year":"2010","journal-title":"Am J Transplant"},{"key":"ref152","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria","volume":"61","author":"F Y Yao","year":"2015","journal-title":"Hepatology"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/lt.23904","article-title":"Alpha-fetoprotein level > 1000 ng\/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria","volume":"200","author":"B Hameed","year":"2014","journal-title":"Liver Transpl"},{"key":"ref154","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"J K Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/hep.30413","article-title":"Alpha-Fetoprotein Decrease from > 1000 to < 500 ng\/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes","volume":"69","author":"N Mehta","year":"2019","journal-title":"Hepatology"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL Clinical Practice Guidelines: Liver transplantation","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.26972","article-title":"Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"59","author":"P Martin","year":"2014","journal-title":"Hepatology"},{"key":"ref158","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.transproceed.2009.03.080","article-title":"Elderly versus young liver transplant recipients: patient and graft survival","volume":"41","author":"G L Adani","year":"2009","journal-title":"Transplant Proc"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/lt.21181","article-title":"Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival","volume":"13","author":"T J Cross","year":"2007","journal-title":"Liver Transpl"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2478\/pjs-2013-0087","article-title":"Short and long-term outcomes after primary liver transplantation in elderly patients","volume":"85","author":"M Gr\u0105t","year":"2013","journal-title":"Pol Przegl Chir"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0025-6196(11)60667-8","article-title":"Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years","volume":"84","author":"J F Aduen","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/archsurg.142.8.775","article-title":"Outcome of liver transplantation in septuagenarians: a single-center experience","volume":"142","author":"G S Lipshutz","year":"2007","journal-title":"Arch Surg"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/TP.0000000000000524","article-title":"Living Donor Liver Transplantation in Patients 70 Years or Older","volume":"99","author":"A Oezcelik","year":"2015","journal-title":"Transplantation"},{"key":"ref164","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12072-011-9286-7","article-title":"Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75\u00a0years","volume":"6","author":"C B Taner","year":"2012","journal-title":"Hepatol Int"},{"key":"ref165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/00365521.2016.1236396","article-title":"Impact of preoperative locoregional therapy on recurrence and patient survival following liver transplantation for hepatocellular carcinoma: a meta-analysis","volume":"52","author":"X Huang","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"ref166","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.29485","article-title":"Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis","volume":"67","author":"L Kulik","year":"2018","journal-title":"Hepatology"},{"key":"ref167","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/TP.0000000000001936","article-title":"Systematic Review and Meta-Analysis of Posttransplant Hepatic Artery and Biliary Complications in Patients Treated With Transarterial Chemoembolization Before Liver Transplantation","volume":"102","author":"D Sneiders","year":"2018","journal-title":"Transplantation"},{"key":"ref168","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(11)70175-9","article-title":"Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report","volume":"13","author":"P A Clavien","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref169","first-page":"143","article-title":"Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival","volume":"6","author":"E W Beal","year":"2016","journal-title":"Front Oncol"},{"key":"ref170","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.transproceed.2017.09.063","article-title":"Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It?","volume":"50","author":"P Cascales-Campos","year":"2018","journal-title":"Transplant Proc"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/liv.12966","article-title":"Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy","volume":"36","author":"A Finkenstedt","year":"2016","journal-title":"Liver Int"},{"key":"ref172","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s10353-017-0487-8","article-title":"Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation","volume":"49","author":"G P Gy\u00f6ri","year":"2017","journal-title":"Eur Surg"},{"key":"ref173","doi-asserted-by":"crossref","first-page":"41624","DOI":"10.1038\/srep41624","article-title":"Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma","volume":"7","author":"L Jianyong","year":"2017","journal-title":"Sci Rep"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.3748\/wjg.v23.i20.3690","article-title":"Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation","volume":"23","author":"D Nicolini","year":"2017","journal-title":"World J Gastroenterol"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejrad.2017.05.022","article-title":"Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization","volume":"93","author":"A Gabr","year":"2017","journal-title":"Eur J Radiol"},{"key":"ref176","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/lt.25492","article-title":"The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation","volume":"25","author":"Q Lai","year":"2019","journal-title":"Liver Transpl"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1148\/radiol.2016160288","article-title":"Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation","volume":"282","author":"H C Oligane","year":"2017","journal-title":"Radiology"},{"key":"ref178","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/lt.21033","article-title":"Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma","volume":"13","author":"G Millonig","year":"2007","journal-title":"Liver Transpl"},{"key":"ref179","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/lt.22397","article-title":"Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy","volume":"17","author":"A Cucchetti","year":"2011","journal-title":"Liver Transpl"},{"key":"ref180","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/lt.23706","article-title":"Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation","volume":"19","author":"Q Lai","year":"2013","journal-title":"Liver Transpl"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/ajt.12684","article-title":"Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size","volume":"14","author":"D J Kim","year":"2014","journal-title":"Am J Transplant"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jama.2010.262","article-title":"Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma","volume":"303","author":"A Riaz","year":"2010","journal-title":"Jama"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/lt.23439","article-title":"Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation","volume":"18","author":"J K O\u2019Connor","year":"2012","journal-title":"Liver Transpl"},{"key":"ref184","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/jso.22104","article-title":"Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response","volume":"105","author":"M E Facciuto","year":"2012","journal-title":"J Surg Oncol"},{"key":"ref185","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","volume":"67","author":"G Sapisochin","year":"2017","journal-title":"J Hepatol"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.suronc.2019.10.006","article-title":"Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium","volume":"33","author":"H Degroote","year":"2019","journal-title":"Surg Oncol"},{"key":"ref187","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/lt.24169","article-title":"Downstaging hepatocellular carcinoma: A systematic review and pooled analysis","volume":"21","author":"N D Parikh","year":"2015","journal-title":"Liver Transpl"},{"key":"ref188","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jamcollsurg.2016.12.020","article-title":"Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions","volume":"224","author":"W C Chapman","year":"2017","journal-title":"J\u00a0Am Coll Surg"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00508-016-1046-1","article-title":"Indications for liver transplantation in adults: Recommendations of the Austrian Society for Gastroenterology and Hepatology (\u00d6GGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX)","volume":"128","author":"I Graziadei","year":"2016","journal-title":"Wien Klin Wochenschr"},{"key":"ref190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma","volume":"154","author":"V Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/SLA.0000000000002964","article-title":"Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies","volume":"268","author":"K J Halazun","year":"2018","journal-title":"Ann Surg"},{"key":"ref192","doi-asserted-by":"crossref","first-page":"453","DOI":"10.21037\/hbsn.2016.08.07","article-title":"Living donor liver transplantation for hepatocellular carcinoma in Seoul National University","volume":"5","author":"S K Hong","year":"2016","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref193","first-page":"224","article-title":"(18)F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma","volume":"5","author":"A Kornberg","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/tri.13586","article-title":"Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion \u2013 a multi-center retrospective cohort study","volume":"33","author":"M Assalino","year":"2020","journal-title":"Transpl Int"},{"key":"ref195","first-page":"182","article-title":"Controversies in criteria for liver transplantation in hepatocellular carcinoma","volume":"32","author":"N D Parik","year":"2016","journal-title":"Curr Opin Gastroenterol"},{"key":"ref196","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma","volume":"151","author":"R Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"ref197","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00268-016-3682-z","article-title":"Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation","volume":"41","author":"G M Ettorre","year":"2017","journal-title":"World J Surg"},{"key":"ref198","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/hep.31234","article-title":"Immunotherapy as a downstaging therapy for liver transplantation","volume":"72","author":"B Schwacha-Eipper","year":"2020","journal-title":"Hepatology"},{"key":"ref199","first-page":"227","article-title":"Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review","volume":"16","author":"N Golse","year":"2018","journal-title":"Exp Clin Transplant"},{"key":"ref200","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12885-015-1373-z","article-title":"Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients \u2013 a prospective, randomized, double-blind, phase III trial","volume":"15","author":"K Hoffmann","year":"2015","journal-title":"BMC Cancer"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/TP.0000000000003196","article-title":"Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference","volume":"104","author":"M Berenguer","year":"2020","journal-title":"Transplantation"},{"key":"ref202","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ajt.15697","article-title":"Liver transplantation for hepatocellular carcinoma: Management after the transplant","volume":"20","author":"E C Verna","year":"2020","journal-title":"Am J Transplant"},{"key":"ref203","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/lt.20391","article-title":"Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression","volume":"11","author":"M Vivarelli","year":"2005","journal-title":"Liver Transpl"},{"key":"ref204","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/SLA.0b013e3181896278","article-title":"Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence","volume":"248","author":"M Vivarelli","year":"2008","journal-title":"Ann Surg"},{"key":"ref205","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"M Rodr\u00edguez-Per\u00e1lvarez","year":"2013","journal-title":"J Hepatol"},{"key":"ref206","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.3748\/wjg.v12.i45.7319","article-title":"Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients","volume":"12","author":"T Decaens","year":"2006","journal-title":"World J Gastroenterol"},{"key":"ref207","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/TP.0000000000002532","article-title":"Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation","volume":"103","author":"P S Tan","year":"2019","journal-title":"Transplantation"},{"key":"ref208","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.trre.2015.02.003","article-title":"mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?","volume":"29","author":"C Duvoux","year":"2015","journal-title":"Transplant Rev (Orlando)"},{"key":"ref209","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fphar.2016.00387","article-title":"Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature","volume":"7","author":"G Tarantino","year":"2016","journal-title":"Front Pharmacol"},{"key":"ref210","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/lt.23658","article-title":"Calcineurin inhibitor-free mycophenolate mofetil\/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial","volume":"19","author":"L Teperman","year":"2013","journal-title":"Liver Transpl"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/lt.21827","article-title":"Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial","volume":"15","author":"P De Simone","year":"2009","journal-title":"Liver Transpl"},{"key":"ref212","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/TP.0000000000000555","article-title":"Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study","volume":"99","author":"L Fischer","year":"2015","journal-title":"Transplantation"},{"key":"ref213","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial","volume":"100","author":"E K Geissler","year":"2016","journal-title":"Transplantation"},{"key":"ref214","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.dld.2009.09.002","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: a\u00a0reappraisal","volume":"42","author":"F Trevisani","year":"2010","journal-title":"Dig Liver Dis"},{"key":"ref215","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/hep.22734","article-title":"Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis","volume":"49","author":"V Paradis","year":"2009","journal-title":"Hepatology"},{"key":"ref216","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study","volume":"63","author":"F Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"ref217","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/ijc.25797","article-title":"Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis","volume":"128","author":"J Ertle","year":"2011","journal-title":"Int J Cancer"},{"key":"ref218","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.suronc.2014.11.001","article-title":"Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review","volume":"23","author":"Y Zhou","year":"2014","journal-title":"Surg Oncol"},{"key":"ref219","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.surg.2012.09.015","article-title":"Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver","volume":"153","author":"W Faber","year":"2013","journal-title":"Surgery"},{"key":"ref220","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/bjs.8963","article-title":"Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome","volume":"100","author":"F Cauchy","year":"2013","journal-title":"Br J Surg"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hpb.2019.07.007","article-title":"Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver","volume":"22","author":"B V Dasari","year":"2020","journal-title":"HPB (Oxford)"},{"key":"ref222","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3390\/cancers11101441","article-title":"The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?","volume":"11","author":"M Ju","year":"2019","journal-title":"Cancers (Basel)"},{"key":"ref223","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ejso.2018.04.018","article-title":"Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis","volume":"44","author":"D Moris","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"ref224","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1245\/s10434-013-3211-3","article-title":"Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis","volume":"21","author":"D J Arnaoutakis","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"ref225","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jamcollsurg.2007.03.002","article-title":"Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers","volume":"205","author":"H Lang","year":"2007","journal-title":"J Am Coll Surg"},{"key":"ref226","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11605-006-0023-9","article-title":"Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver. A 116-case European series","volume":"11","author":"T B\u00e8ge","year":"2007","journal-title":"J Gastrointest Surg"},{"key":"ref227","first-page":"4195076","article-title":"Adrenal Metastasis of Hepatocellular Carcinoma in Patients following Liver Resection or Liver Transplantation: Experience from a Tertiary Referral Center","volume":"2018","author":"E M Teegen","year":"2018","journal-title":"Int J Surg Oncol"},{"key":"ref228","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jso.25184","article-title":"Comparison of the ability of Child-Pugh score, MELD score, and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma","volume":"118","author":"Y Y Wang","year":"2018","journal-title":"J Surg Oncol"},{"key":"ref229","doi-asserted-by":"crossref","first-page":"016005","DOI":"10.1088\/1752-7163\/aa820b","article-title":"Kinetic validation of the LiMAx test during 10 000 intravenous (13)C-methacetin breath tests","volume":"12","author":"T M Rubin","year":"2017","journal-title":"J Breath Res"},{"key":"ref230","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/SLA.0b013e3181ad85b5","article-title":"Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity","volume":"250","author":"M Stockmann","year":"2009","journal-title":"Ann Surg"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"e0190512","DOI":"10.1371\/journal.pone.0190512","article-title":"Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection: A\u00a0meta-analysis","volume":"13","author":"Z Huang","year":"2018","journal-title":"PLoS One"},{"key":"ref232","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.mayocp.2018.12.020","article-title":"Portal Hypertension and Related Complications: Diagnosis and Management","volume":"94","author":"D A Simonetto","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"ref233","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/hep.27745","article-title":"The role of hepatic resection in the treatment of hepatocellular cancer","volume":"62","author":"S Roayaie","year":"2015","journal-title":"Hepatology"},{"key":"ref234","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1053\/j.gastro.2008.02.091","article-title":"Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma","volume":"134","author":"T Ishizawa","year":"2008","journal-title":"Gastroenterology"},{"key":"ref235","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/SLA.0b013e31828329b8","article-title":"A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL\/AASLD recommendations?: an observational study of the HCC East-West study group","volume":"257","author":"G Torzilli","year":"2013","journal-title":"Ann Surg"},{"key":"ref236","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4254\/wjh.v10.i6.433","article-title":"Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence","volume":"10","author":"Y X Koh","year":"2018","journal-title":"World J Hepatol"},{"key":"ref237","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/SLA.0000000000001866","article-title":"Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria","volume":"264","author":"V M Zaydfudim","year":"2016","journal-title":"Ann Surg"},{"key":"ref238","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1245\/s10434-020-08452-3","article-title":"Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria","volume":"27","author":"D I Tsilimigras","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"ref239","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4254\/wjh.v7.i2.245","article-title":"Surgical management of hepatocellular carcinoma","volume":"7","author":"T C Pang","year":"2015","journal-title":"World J Hepatol"},{"key":"ref240","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.hpb.2017.04.010","article-title":"A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence","volume":"19","author":"X Feng","year":"2017","journal-title":"HPB (Oxford)"},{"key":"ref241","first-page":"619","article-title":"Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka","volume":"261","author":"G Wakabayashi","year":"2015","journal-title":"Ann Surg"},{"key":"ref242","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/SLA.0000000000002151","article-title":"Laparoscopic Liver Resection: An Ongoing Revolution","volume":"265","author":"D Cherqui","year":"2017","journal-title":"Ann Surg"},{"key":"ref243","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.suronc.2018.10.005","article-title":"Minimal-invasive versus open hepatectomy for hepatocellular carcinoma: Comparison of postoperative outcomes and long-term survivals using propensity score matching analysis","volume":"27","author":"A Andreou","year":"2018","journal-title":"Surg Oncol"},{"key":"ref244","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.suronc.2018.12.001","article-title":"Laparoscopic liver surgery in cirrhosis \u2013 Addressing lesions in posterosuperior segments","volume":"28","author":"P K Haber","year":"2019","journal-title":"Surg Oncol"},{"key":"ref245","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00464-018-6426-3","article-title":"Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry","volume":"33","author":"G B Levi Sandri","year":"2019","journal-title":"Surg Endosc"},{"key":"ref246","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s13304-015-0323-2","article-title":"Salvage liver transplantation after laparoscopic resection for hepatocellular carcinoma: a multicenter experience","volume":"67","author":"E Felli","year":"2015","journal-title":"Updates Surg"},{"key":"ref247","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"J Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref248","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma","volume":"148","author":"J H Lee","year":"2015","journal-title":"Gastroenterology"},{"key":"ref249","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.21415","article-title":"Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis","volume":"44","author":"V Mazzaferro","year":"2006","journal-title":"Hepatology"},{"key":"ref250","first-page":"Cd001199","article-title":"Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma","volume":"1","author":"M Samuel","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0140-6736(00)02654-4","article-title":"Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial","volume":"356","author":"T Takayama","year":"2000","journal-title":"Lancet"},{"key":"ref252","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.sla.0000201480.65519.b8","article-title":"A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma","volume":"243","author":"M S Chen","year":"2006","journal-title":"Ann Surg"},{"key":"ref253","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","article-title":"A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma","volume":"57","author":"K Feng","year":"2012","journal-title":"J Hepatol"},{"key":"ref254","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/SLA.0b013e3181efc656","article-title":"A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria","volume":"252","author":"J Huang","year":"2010","journal-title":"Ann Surg"},{"key":"ref255","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/bjs.10677","article-title":"Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma","volume":"104","author":"K KC Ng","year":"2017","journal-title":"Br J Surg"},{"key":"ref256","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jhep.2014.03.012","article-title":"Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT","volume":"61","author":"L Yin","year":"2014","journal-title":"J Hepatol"},{"key":"ref257","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"R Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"ref258","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5152\/eajm.2014.07","article-title":"Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study","volume":"46","author":"M A Wahab","year":"2014","journal-title":"Eurasian J Med"},{"key":"ref259","first-page":"898","article-title":"Univariate and multivariate analysis of prognostic factors in the surgical treatment of hepatocellular carcinoma in cirrhotic patients","volume":"53","author":"G Ramacciato","year":"2006","journal-title":"Hepatogastroenterology"},{"key":"ref260","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/jgh.12791","article-title":"Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial","volume":"30","author":"G G Di Costanzo","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.dld.2013.10.015","article-title":"An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma","volume":"46","author":"A Cucchetti","year":"2014","journal-title":"Dig Liver Dis"},{"key":"ref262","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-230X-11-143","article-title":"Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma","volume":"11","author":"H Nishikawa","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"ref263","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s00330-018-5902-4","article-title":"Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database","volume":"29","author":"J Uhlig","year":"2019","journal-title":"Eur Radiol"},{"key":"ref264","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jus.2009.05.003","article-title":"Radiofrequency ablation of hepatocellular carcinoma in patients with and without cirrhosis","volume":"12","author":"A Salmi","year":"2009","journal-title":"J Ultrasound"},{"key":"ref265","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jso.24113","article-title":"Assessment of non-surgical versus surgical therapy for localized hepatocellular carcinoma","volume":"113","author":"S Mohanty","year":"2016","journal-title":"J Surg Oncol"},{"key":"ref266","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2169\/internalmedicine.0973-18","article-title":"Hepatocellular Carcinoma Arising in a Non-cirrhotic Liver with Secondary Hemochromatosis","volume":"58","author":"R Yamauchi","year":"2019","journal-title":"Intern Med"},{"key":"ref267","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1148\/radiology.210.3.r99fe40655","article-title":"Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection","volume":"210","author":"T Livraghi","year":"1999","journal-title":"Radiology"},{"key":"ref268","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1148\/radiol.2281020718","article-title":"Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection","volume":"228","author":"R A Lencioni","year":"2003","journal-title":"Radiology"},{"key":"ref269","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2004.09.003","article-title":"Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm","volume":"127","author":"S M Lin","year":"2004","journal-title":"Gastroenterology"},{"key":"ref270","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver","volume":"35","author":"J Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.gastro.2005.04.009","article-title":"A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma","volume":"129","author":"S Shiina","year":"2005","journal-title":"Gastroenterology"},{"key":"ref272","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/00365520701885481","article-title":"Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial","volume":"43","author":"F Brunello","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"ref273","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/gut.2004.045203","article-title":"Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less","volume":"54","author":"S M Lin","year":"2005","journal-title":"Gut"},{"issue":"S 01","key":"ref274","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000048278","article-title":"Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation","volume":"62","author":"S Shiina","year":"2002","journal-title":"Oncology"},{"key":"ref275","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1002\/hep.30591","article-title":"Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis","volume":"69","author":"K Hara","year":"2019","journal-title":"Hepatology"},{"key":"ref276","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2012.42.9936","article-title":"Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial","volume":"31","author":"Z W Peng","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref277","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/bjs.10061","article-title":"Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria","volume":"103","author":"H Liu","year":"2016","journal-title":"Br J Surg"},{"key":"ref278","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1080\/00365521.2018.1548645","article-title":"Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma","volume":"53","author":"K Endo","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"ref279","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.hpb.2017.08.011","article-title":"Evaluation of hepatocellular carcinoma spread via the portal system by 3-dimensional mapping","volume":"19","author":"S Fukutomi","year":"2017","journal-title":"HPB (Oxford)"},{"key":"ref280","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00261-018-1464-9","article-title":"Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone","volume":"43","author":"A R Smolock","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00270-012-0341-0","article-title":"Combined therapies for the treatment of technically unresectable liver malignancies: bland embolization and radiofrequency thermal ablation within the same session","volume":"35","author":"G Bonomo","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref282","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"C M Lo","year":"2002","journal-title":"Hepatology"},{"key":"ref283","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"J Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref284","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"J M Llovet","year":"2002","journal-title":"Lancet"},{"key":"ref285","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bjc.2014.199","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma","volume":"111","author":"R Golfieri","year":"2014","journal-title":"Br J Cancer"},{"key":"ref286","doi-asserted-by":"crossref","first-page":"348","DOI":"10.21037\/jgo.2019.01.01","article-title":"Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC)","volume":"10","author":"R Yamada","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"ref287","first-page":"Cd011313","article-title":"Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma","volume":"1","author":"O Abdel-Rahman","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref288","doi-asserted-by":"crossref","first-page":"299","DOI":"10.20892\/j.issn.2095-3941.2017.0177","article-title":"Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"15","author":"Y Yang","year":"2018","journal-title":"Cancer Biol Med"},{"key":"ref289","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00330-016-4548-3","article-title":"Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus (90)Y-radioembolization for hepatocellular carcinoma","volume":"27","author":"J M Ludwig","year":"2017","journal-title":"Eur Radiol"},{"key":"ref290","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.2147\/OTT.S175715","article-title":"Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials","volume":"11","author":"A Casadei Gardini","year":"2018","journal-title":"Onco Targets Ther"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/liv.12750","article-title":"Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma","volume":"35","author":"F T Kolligs","year":"2015","journal-title":"Liver Int"},{"key":"ref292","doi-asserted-by":"crossref","first-page":"e0184597","DOI":"10.1371\/journal.pone.0184597","article-title":"Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials","volume":"12","author":"K Katsanos","year":"2017","journal-title":"PLoS One"},{"key":"ref293","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00270-014-1012-0","article-title":"Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma","volume":"38","author":"M B Pitton","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref294","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s00270-016-1426-y","article-title":"Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis","volume":"39","author":"L Lobo","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref295","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.cgh.2013.04.028","article-title":"Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization","volume":"11","author":"R Salem","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref296","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00259-018-3968-5","article-title":"Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies","volume":"45","author":"B Sangro","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref297","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jvir.2016.03.046","article-title":"Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma","volume":"27","author":"G E Johnson","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"ref298","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.23944","article-title":"Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival","volume":"52","author":"P Hilgard","year":"2010","journal-title":"Hepatology"},{"key":"ref299","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","article-title":"Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation","volume":"54","author":"B Sangro","year":"2011","journal-title":"Hepatology"},{"key":"ref300","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.21980","article-title":"Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis","volume":"47","author":"L M Kulik","year":"2008","journal-title":"Hepatology"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","article-title":"Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study","volume":"57","author":"V Mazzaferro","year":"2013","journal-title":"Hepatology"},{"key":"ref302","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"R Salem","year":"2010","journal-title":"Gastroenterology"},{"key":"ref303","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2017.11.013","article-title":"Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review","volume":"129","author":"C H Rim","year":"2018","journal-title":"Radiother Oncol"},{"issue":"S 04","key":"ref304","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"A Vogel","year":"2018","journal-title":"Ann Oncol"},{"key":"ref305","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5009\/gnl19024","article-title":"2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma","volume":"13","year":"2019","journal-title":"Gut Liver"},{"key":"ref306","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2017.2303","article-title":"Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial","volume":"4","author":"M Feng","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref307","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.dld.2018.11.004","article-title":"Phase I\/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma","volume":"51","author":"J W Kim","year":"2019","journal-title":"Dig Liver Dis"},{"key":"ref308","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.radonc.2018.01.004","article-title":"A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy","volume":"126","author":"D H Moon","year":"2018","journal-title":"Radiother Oncol"},{"key":"ref309","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/cncr.30008","article-title":"Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation","volume":"122","author":"A Takeda","year":"2016","journal-title":"Cancer"},{"key":"ref310","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.prro.2015.02.007","article-title":"Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1\u20132 trial of stereotactic body radiation therapy","volume":"5","author":"F D Lasley","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00432-015-1929-y","article-title":"The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)","volume":"141","author":"M Scorsetti","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref312","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"A Bujold","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref313","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/02841860600897934","article-title":"Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study","volume":"45","author":"A M\u00e9ndez Romero","year":"2006","journal-title":"Acta Oncol"},{"key":"ref314","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.radonc.2018.12.005","article-title":"Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies","volume":"131","author":"C H Rim","year":"2019","journal-title":"Radiother Oncol"},{"key":"ref315","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.radonc.2019.12.004","article-title":"Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review","volume":"145","author":"J Lee","year":"2020","journal-title":"Radiother Oncol"},{"issue":"06","key":"ref316","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.2017.75.3228","article-title":"Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database","volume":"36","author":"D J Rajyaguru","year":"2018","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref317","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma","volume":"34","author":"D R Wahl","year":"2016","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref318","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","article-title":"Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma","volume":"100","author":"E Sapir","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref319","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00270-018-2127-5","article-title":"Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial","volume":"42","author":"K Mohnike","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref320","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00066-014-0781-3","article-title":"CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma","volume":"191","author":"F Collettini","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijrobp.2009.07.1700","article-title":"Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival","volume":"78","author":"K Mohnike","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref322","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ijrobp.2008.10.073","article-title":"A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma","volume":"74","author":"N Fukumitsu","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref323","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijrobp.2016.02.027","article-title":"Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis","volume":"95","author":"D A Bush","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref324","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4143\/crt.2013.218","article-title":"Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma","volume":"47","author":"T H Kim","year":"2015","journal-title":"Cancer Res Treat"},{"key":"ref325","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","volume":"34","author":"T S Hong","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref326","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.ijrobp.2010.03.015","article-title":"Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract","volume":"80","author":"H Nakayama","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref327","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1002\/cncr.24619","article-title":"Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience","volume":"115","author":"H Nakayama","year":"2009","journal-title":"Cancer"},{"key":"ref328","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ijrobp.2007.09.056","article-title":"Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis","volume":"71","author":"M Mizumoto","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref329","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ijrobp.2009.02.030","article-title":"Proton beam therapy for large hepatocellular carcinoma","volume":"76","author":"S Sugahara","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref330","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00261-017-1334-x","article-title":"LI-RADS categories: concepts, definitions, and criteria","volume":"43","author":"C Santillan","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00261-017-1291-4","article-title":"LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents","volume":"43","author":"C Santillan","year":"2018","journal-title":"Abdom Radiol (NY)"},{"issue":"S 01","key":"ref332","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000111714","article-title":"Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy","volume":"72","author":"S Takahashi","year":"2007","journal-title":"Oncology"},{"key":"ref333","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1572-0241.2007.01604.x","article-title":"Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response","volume":"103","author":"A Guglielmi","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"ref334","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jvir.2009.11.014","article-title":"Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas","volume":"21","author":"J H Yoon","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"ref335","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1477-2574.2010.00181.x","article-title":"Pretreatment assessment of hepatocellular carcinoma: expert consensus statement","volume":"12","author":"J N Vauthey","year":"2010","journal-title":"HPB (Oxford)"},{"key":"ref336","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1102\/1470-7330.2007.9047","article-title":"Post-treatment imaging of liver tumours","volume":"7","author":"W Schima","year":"2007","journal-title":"Cancer Imaging"},{"key":"ref337","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-0029-1245934","article-title":"Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies","volume":"32","author":"M Frieser","year":"2011","journal-title":"Ultraschall in Med"},{"key":"ref338","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000218342","article-title":"Transabdominal ultrasound with echoenhancement by contrast media in the diagnosis of hepatocellular carcinoma","volume":"27","author":"D Schacherer","year":"2009","journal-title":"Dig Dis"},{"key":"ref339","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jhep.2008.02.005","article-title":"Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma","volume":"48","author":"R Lencioni","year":"2008","journal-title":"J Hepatol"},{"key":"ref340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00270-009-9736-y","article-title":"Quality improvement guidelines for radiofrequency ablation of liver tumours","volume":"33","author":"L Crocetti","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1440-1746.2009.06115.x","article-title":"Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation","volume":"25","author":"M C Tsai","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"ref342","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1158\/1078-0432.CCR-12-3796","article-title":"New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma","volume":"19","author":"R Lencioni","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref343","doi-asserted-by":"crossref","first-page":"e0133488","DOI":"10.1371\/journal.pone.0133488","article-title":"Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis","volume":"10","author":"B Vincenzi","year":"2015","journal-title":"PLoS One"},{"key":"ref344","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"R S Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"ref345","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"A L Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref346","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"J M Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"ref347","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"M Kudo","year":"2018","journal-title":"The Lancet"},{"key":"ref348","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"J Bruix","year":"2017","journal-title":"The Lancet"},{"key":"ref349","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"G K Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"ref350","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"A X Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"J M Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"ref352","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"A X Zhu","year":"2019","journal-title":"The Lancet Oncology"},{"key":"ref353","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"C Cainap","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref354","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"P J Johnson","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref355","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","article-title":"SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma","volume":"33","author":"A X Zhu","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref356","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"A L Cheng","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref357","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"J Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref358","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"M Reig","year":"2013","journal-title":"Hepatology"},{"key":"ref359","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"A B El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"ref360","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"A X Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"R S Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref362","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study","volume":"65","author":"J A Marrero","year":"2016","journal-title":"J Hepatol"},{"key":"ref363","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1158\/1078-0432.CCR-16-0919","article-title":"Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study","volume":"23","author":"T M Ganten","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref364","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10637-018-0621-x","article-title":"Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study","volume":"36","author":"C RG Leal","year":"2018","journal-title":"Invest New Drugs"},{"key":"ref365","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mds343","article-title":"Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis","volume":"24","author":"T Pressiani","year":"2013","journal-title":"Ann Oncol"},{"key":"ref366","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10637-015-0237-3","article-title":"Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors","volume":"33","author":"S Ogasawara","year":"2015","journal-title":"Invest New Drugs"},{"key":"ref367","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/cncr.32206","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series","volume":"125","author":"S Kambhampati","year":"2019","journal-title":"Cancer"},{"key":"ref368","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"V Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref369","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"V Vilgrain","year":"2017","journal-title":"The Lancet Oncology"},{"key":"ref370","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma","volume":"36","author":"P KH Chow","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref371","first-page":"CD011313","article-title":"Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma","volume":"1","author":"O Abdel-Rahman","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref372","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial","volume":"64","author":"R Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"ref373","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"T Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref374","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma","volume":"36","author":"P KH Chow","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref375","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"T Meyer","year":"2017","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"ref376","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"J Ricke","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"ref377","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"M Kudo","year":"2020","journal-title":"Gut"},{"key":"ref378","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/hepr.13394","article-title":"Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version)","volume":"49","author":"M Kudo","year":"2019","journal-title":"Hepatol Res"},{"issue":"S 03","key":"ref379","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/JCO.2021.39.3_suppl.270","article-title":"TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC)","volume":"39","author":"M Kudo","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"ref380","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"J Bruix","year":"2015","journal-title":"The Lancet Oncology"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.2002.06.155","article-title":"Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children\u2019s Cancer Group intergroup study","volume":"20","author":"H M Katzenstein","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref382","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2002.06.102","article-title":"Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group","volume":"20","author":"P Czauderna","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref383","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/JHC.S94008","article-title":"Pediatric hepatocellular carcinoma: challenges and solutions","volume":"4","author":"I Schmid","year":"2017","journal-title":"J Hepatocell Carcinoma"},{"key":"ref384","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/pbc.23295","article-title":"Sorafenib and cisplatin\/doxorubicin (PLADO) in pediatric hepatocellular carcinoma","volume":"58","author":"I Schmid","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"ref385","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.clnu.2014.11.007","article-title":"Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC)","volume":"34","author":"K Sch\u00fctte","year":"2015","journal-title":"Clin Nutr"},{"key":"ref386","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.hpb.2019.01.003","article-title":"Malnutrition associated with an increased risk of postoperative complications following hepatectomy in patients with hepatocellular carcinoma","volume":"21","author":"T H Huang","year":"2019","journal-title":"HPB (Oxford)"},{"key":"ref387","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"J Arends","year":"2017","journal-title":"Clin Nutr"},{"key":"ref388","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s13304-011-0121-4","article-title":"Nutritional aspects in patient undergoing liver resection","volume":"63","author":"R Ciuni","year":"2011","journal-title":"Updates Surg"},{"key":"ref389","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jcsm.12383","article-title":"GLIM criteria for the diagnosis of malnutrition \u2013 A\u00a0consensus report from the global clinical nutrition community","volume":"10","author":"T Cederholm","year":"2019","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"ref390","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2015.02.031","article-title":"Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma","volume":"63","author":"N Fujiwara","year":"2015","journal-title":"J Hepatol"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.31557\/APJCP.2020.21.11.3285","article-title":"Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients","volume":"21","author":"H Badran","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref392","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00262-020-02794-3","article-title":"Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab","volume":"70","author":"N Kim","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"ref393","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12876-019-1152-4","article-title":"Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study","volume":"19","author":"Y Mardian","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"ref394","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/SLA.0000000000000743","article-title":"Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma","volume":"261","author":"T Voron","year":"2015","journal-title":"Ann Surg"},{"key":"ref395","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clnu.2018.12.022","article-title":"ESPEN guideline on clinical nutrition in liver disease","volume":"38","author":"M Plauth","year":"2019","journal-title":"Clin Nutr"},{"key":"ref396","first-page":"CD011129","article-title":"Early palliative care for adults with advanced cancer","volume":"6","author":"M W Haun","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref397","first-page":"660","article-title":"[Integration of palliative care into intensive care: Systematic review]","volume":"66","author":"K Adler","year":"2017","journal-title":"Anaesthesist"},{"key":"ref398","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1017\/S1478951513001338","article-title":"Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome","volume":"12","author":"K M Dalgaard","year":"2014","journal-title":"Palliat Support Care"},{"key":"ref399","first-page":"99","article-title":"A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses","volume":"4","author":"M P Davis","year":"2015","journal-title":"Ann Palliat Med"},{"key":"ref400","doi-asserted-by":"crossref","first-page":"j2925","DOI":"10.1136\/bmj.j2925","article-title":"Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis","volume":"357","author":"J Gaertner","year":"2017","journal-title":"BMJ"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1634\/theoncologist.2014-0312","article-title":"Integration of oncology and palliative care: a systematic review","volume":"20","author":"D Hui","year":"2015","journal-title":"Oncologist"},{"key":"ref402","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1634\/theoncologist.2016-0006","article-title":"Referral Criteria for Outpatient Palliative Cancer Care: A\u00a0Systematic Review","volume":"21","author":"D Hui","year":"2016","journal-title":"Oncologist"},{"key":"ref403","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1574887110666151014141650","article-title":"Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature","volume":"11","author":"D Tassinari","year":"2016","journal-title":"Rev Recent Clin Trials"},{"key":"ref404","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1634\/theoncologist.2015-0015","article-title":"Surprise Questions for Survival Prediction in Patients With Advanced Cancer: A Multicenter Prospective Cohort Study","volume":"20","author":"J Hamano","year":"2015","journal-title":"Oncologist"},{"key":"ref405","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/0269216314526273","article-title":"The \u201csurprise\u201d question in advanced cancer patients: A prospective study among general practitioners","volume":"28","author":"M Moroni","year":"2014","journal-title":"Palliat Med"},{"key":"ref406","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/0269216311401949","article-title":"Using the \u201csurprise question\u201d can identify people with advanced heart failure and COPD who would benefit from a palliative care approach","volume":"25","author":"S Murray","year":"2011","journal-title":"Palliat Med"},{"key":"ref407","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/jpm.2010.0018","article-title":"Prognostic significance of the \u201csurprise\u201d question in cancer patients","volume":"13","author":"A H Moss","year":"2010","journal-title":"J Palliat Med"},{"key":"ref408","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Electronic address, e.e.e. and L. European Association for the Study of the, EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"ref409","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2165\/00003495-200868150-00006","article-title":"Pathogenesis and treatment of pruritus in cholestasis","volume":"68","author":"A E Kremer","year":"2008","journal-title":"Drugs"},{"key":"ref410","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/ddg.13304_g","article-title":"S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus \u2013 Update \u2013 Kurzversion","volume":"15","author":"S Stander","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref411","first-page":"456","article-title":"Pathogenesis of pruritus","volume":"9","author":"S Stander","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref412","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0140-6736(89)91608-5","article-title":"Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis","volume":"1","author":"L Bachs","year":"1989","journal-title":"Lancet"},{"key":"ref413","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial","volume":"94","author":"C N Ghent","year":"1988","journal-title":"Gastroenterology"},{"key":"ref414","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study","volume":"37","author":"R Terg","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"ref415","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0016-5085(92)90102-5","article-title":"A controlled trial of naloxone infusions for the pruritus of chronic cholestasis","volume":"102","author":"N V Bergasa","year":"1992","journal-title":"Gastroenterology"},{"key":"ref416","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"M J Mayo","year":"2007","journal-title":"Hepatology"},{"key":"ref417","first-page":"691","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group","volume":"336","author":"K D Lindor","year":"1997","journal-title":"N Engl J Med"},{"key":"ref418","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1542-3565(03)00134-4","article-title":"Natural history of pruritus in primary biliary cirrhosis","volume":"1","author":"J A Talwalkar","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref419","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1478-3231.2004.0996.x","article-title":"Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience","volume":"25","author":"R Zapata","year":"2005","journal-title":"Liver Int"},{"key":"ref420","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1016\/j.lpm.2009.09.027","article-title":"Aerobic capacity in patients with chronic liver disease: Very modest effect of liver transplantation","volume":"39","author":"M Lemyze","year":"2010","journal-title":"Presse Med"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/lt.20088","article-title":"Aerobic capacity is associated with 100-day outcome after hepatic transplantation","volume":"10","author":"S K Epstein","year":"2004","journal-title":"Liver Transpl"},{"key":"ref422","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00421-007-0435-6","article-title":"Physical fitness, fatigue, and quality of life after liver transplantation","volume":"100","author":"B T van Ginneken","year":"2007","journal-title":"Eur J Appl Physiol"},{"key":"ref423","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/lt.20684","article-title":"Fatigue is a major problem after liver transplantation","volume":"12","author":"R van den Berg-Emons","year":"2006","journal-title":"Liver Transpl"},{"key":"ref424","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3109\/09638288.2010.482174","article-title":"Effects of a rehabilitation programme on daily functioning, participation, health-related quality of life, anxiety and depression in liver transplant recipients","volume":"32","author":"B T van Ginneken","year":"2010","journal-title":"Disabil Rehabil"},{"key":"ref425","first-page":"55","article-title":"[Changes in quality of life in oncological patients in the course of an inpatient after-care program]","volume":"30","author":"G Schwibbe","year":"1991","journal-title":"Rehabilitation (Stuttg)"},{"key":"ref426","first-page":"501","article-title":"[Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation]","volume":"91","author":"U G\u00e4rtner","year":"1996","journal-title":"Med Klin (Munich)"},{"key":"ref427","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/pon.3146","article-title":"Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping","volume":"22","author":"S Y Fan","year":"2013","journal-title":"Psychooncology"},{"key":"ref428","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.cgh.2010.03.008","article-title":"Health-related quality of life in patients with hepatocellular carcinoma: a systematic review","volume":"8","author":"S Y Fan","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref429","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3748\/wjg.v18.i21.2689","article-title":"Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma","volume":"18","author":"C X Qiao","year":"2012","journal-title":"World J Gastroenterol"},{"key":"ref430","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1200\/JCO.2006.06.4592","article-title":"Depression, immunity, and survival in patients with hepatobiliary carcinoma","volume":"25","author":"J L Steel","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jad.2018.12.085","article-title":"Impact of preoperative anxiety and depression on quality of life before and after resection of hepatocellular carcinoma","volume":"246","author":"H H Lee","year":"2019","journal-title":"J Affect Disord"},{"key":"ref432","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/NCC.0b013e3181ac6248","article-title":"The mediating effects of depression on sleep disturbance and fatigue: symptom clusters in patients with hepatocellular carcinoma","volume":"32","author":"T W Huang","year":"2009","journal-title":"Cancer Nurs"},{"key":"ref433","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/pon.3705","article-title":"Suicide in cancer patients within the first year of diagnosis","volume":"24","author":"M H Ahn","year":"2015","journal-title":"Psychooncology"},{"key":"ref434","first-page":"65","article-title":"Health-Related Quality of Life before and after Surgical Resection of Hepatocellular Carcinoma: A Prospective Study","volume":"19","author":"C C Chiu","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref435","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1634\/theoncologist.2011-0368","article-title":"Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study","volume":"17","author":"S C Shun","year":"2012","journal-title":"Oncologist"},{"key":"ref436","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/NCC.0000000000000403","article-title":"The Role of Age in Change in Unmet Supportive Care Needs in Hepatocellular Carcinoma Patients During Transition From Hospital to Home","volume":"40","author":"S C Shun","year":"2017","journal-title":"Cancer Nurs"},{"key":"ref437","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3748\/wjg.14.931","article-title":"Psychological intervention reduces postembolization pain during hepatic arterial chemoembolization therapy: a complementary approach to drug analgesia","volume":"14","author":"Z X Wang","year":"2008","journal-title":"World J Gastroenterol"},{"key":"ref438","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<226::AID-CNCR30>3.0.CO;2-P","article-title":"The unmet supportive care needs of patients with cancer. Supportive Care Review Group","volume":"88","author":"R Sanson-Fisher","year":"2000","journal-title":"Cancer"},{"key":"ref439","first-page":"303","article-title":"Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study","volume":"13","author":"U R Kleeberg","year":"2005","journal-title":"Support Care Cancer"},{"key":"ref440","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(03)15392-5","article-title":"Communicating sad, bad, and difficult news in medicine","volume":"363","author":"L Fallowfield","year":"2004","journal-title":"Lancet"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0738-3991(99)00108-1","article-title":"Doctor-patient communication and cancer patients\u2019 quality of life and satisfaction","volume":"41","author":"L M Ong","year":"2000","journal-title":"Patient Educ Couns"},{"key":"ref442","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.cco.0000167735.26454.79","article-title":"Communication in palliative care: a review of recent literature","volume":"17","author":"H de Haes","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"ref443","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/cncr.23710","article-title":"A randomized study assessing the efficacy of communication skill training on patients\u2019 psychologic distress and coping: nurses\u2019 communication with patients just after being diagnosed with cancer","volume":"113","author":"S Fukui","year":"2008","journal-title":"Cancer"},{"key":"ref444","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2003.08.031","article-title":"How to optimize physicians\u2019 communication skills in cancer care: results of a randomized study assessing the usefulness of posttraining consolidation workshops","volume":"21","author":"D Razavi","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref445","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/pon.1262","article-title":"Factors that influence cancer patients\u2019 and relatives\u2019 anxiety following a three-person medical consultation: impact of a communication skills training program for physicians","volume":"17","author":"A Lienard","year":"2008","journal-title":"Psychooncology"},{"key":"ref446","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1369-7625.2006.00401.x","article-title":"Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision","volume":"9","author":"A Edwards","year":"2006","journal-title":"Health Expect"},{"key":"ref447","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pec.2009.06.009","article-title":"Shared decision making coding systems: how do they compare in the oncology context?","volume":"78","author":"P Butow","year":"2010","journal-title":"Patient Educ Couns"},{"key":"ref448","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1399-0012.2011.01480.x","article-title":"Are informed consent forms for organ transplantation and donation too difficult to read?","volume":"26","author":"E J Gordon","year":"2012","journal-title":"Clin Transplant"},{"key":"ref449","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/lt.22437","article-title":"Patient decision making about organ quality in liver transplantation","volume":"17","author":"M L Volk","year":"2011","journal-title":"Liver Transpl"},{"key":"ref450","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/lt.22355","article-title":"Patients\u2019 expectations and success criteria for liver transplantation","volume":"17","author":"J R Rodrigue","year":"2011","journal-title":"Liver Transpl"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1749-6632.1997.tb48095.x","article-title":"Communication with cancer patients in culturally diverse societies","volume":"809","author":"P N Butow","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"ref452","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/(SICI)1099-1611(200003\/04)9:2<147::AID-PON443>3.0.CO;2-X","article-title":"Communication styles in the cancer consultation: preferences for a patient-centred approach","volume":"90","author":"S M Dowsett","year":"2000","journal-title":"Psychooncology"},{"key":"ref453","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pec.2005.11.003","article-title":"Making communication research matter: what do patients notice, what do patients want, and what do patients need?","volume":"60","author":"R M Epstein","year":"2006","journal-title":"Patient Educ Couns"},{"key":"ref454","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.bjc.6600798","article-title":"Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease","volume":"88","author":"R Zachariae","year":"2003","journal-title":"Br J Cancer"},{"key":"ref455","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jpainsymman.2004.08.011","article-title":"Impact of physician sitting versus standing during inpatient oncology consultations: patients\u2019 preference and perception of compassion and duration. A randomized controlled trial","volume":"29","author":"F Strasser","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"ref456","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.1999.17.1.371","article-title":"Can 40 seconds of compassion reduce patient anxiety?","volume":"17","author":"L A Fogarty","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref458","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000342813","article-title":"Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation","volume":"86","author":"N Ashoori","year":"2012","journal-title":"Digestion"},{"key":"ref459","doi-asserted-by":"crossref","first-page":"e13255","DOI":"10.1111\/ctr.13255","article-title":"The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study","volume":"32","author":"A Boteon","year":"2018","journal-title":"Clin Transplant"},{"key":"ref460","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jvir.2018.11.037","article-title":"Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study","volume":"30","author":"P Habibollahi","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/hep.20688","article-title":"Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation","volume":"41","author":"D S Lu","year":"2005","journal-title":"Hepatology"},{"key":"ref462","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jvir.2009.10.038","article-title":"Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma","volume":"21","author":"A Nicolini","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"ref463","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jvir.2018.12.736","article-title":"Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort","volume":"30","author":"T Sandow","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"ref464","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14701\/ahbps.2018.22.1.27","article-title":"Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?","volume":"22","author":"C HN Tan","year":"2018","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"ref465","first-page":"638","article-title":"Neoadjuvant Transarterial Chemoembolization Improves Survival After Liver Transplant in Patients With Hepatocellular Carcinoma","volume":"17","author":"J D Werner","year":"2019","journal-title":"Exp Clin Transplant"},{"key":"ref466","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2011.05.020","article-title":"Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early\/early stage hepatocellular carcinoma","volume":"56","author":"J H Wang","year":"2012","journal-title":"J Hepatol"},{"key":"ref467","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1148\/radiol.11110817","article-title":"Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study","volume":"262","author":"Z W Peng","year":"2012","journal-title":"Radiology"},{"key":"ref468","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2012.11.009","article-title":"Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey","volume":"58","author":"K Hasegawa","year":"2013","journal-title":"J Hepatol"},{"key":"ref469","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/jgh.12441","article-title":"Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma","volume":"29","author":"Y Fang","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"ref470","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/hpb.12446","article-title":"Surgical resection versus ablation for hepatocellular carcinoma \u2264 3 cm: a population-based analysis","volume":"17","author":"J T Miura","year":"2015","journal-title":"HPB (Oxford)"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.2147\/OTT.S141968","article-title":"Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis","volume":"10","author":"M Zhang","year":"2017","journal-title":"Onco Targets Ther"},{"key":"ref472","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/02656736.2016.1257824","article-title":"Microwave ablation versus hepatic resection for the treatment of hepatocellular carcinoma and oesophageal variceal bleeding in cirrhotic patients","volume":"33","author":"Q B Zhang","year":"2017","journal-title":"Int J Hyperthermia"},{"key":"ref473","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/SLA.0000000000001178","article-title":"Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma \u2264 2 \u200acm in a Propensity Score Model","volume":"263","author":"P H Liu","year":"2016","journal-title":"Ann Surg"},{"key":"ref474","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/liv.13670","article-title":"Impact of resection and ablation for single hypovascular hepatocellular carcinoma \u22642 cm analysed with propensity score weighting","volume":"38","author":"K Takayasu","year":"2018","journal-title":"Liver Int"},{"key":"ref475","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cgh.2010.08.018","article-title":"Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas","volume":"9","author":"H H Hung","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref476","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/13651820510028846","article-title":"Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes","volume":"7","author":"M Ogihara","year":"2005","journal-title":"HPB (Oxford)"},{"key":"ref477","first-page":"801","article-title":"[Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial]","volume":"86","author":"M D L\u00fc","year":"2006","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref478","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/13651820701713758","article-title":"Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection?","volume":"9","author":"L Lupo","year":"2007","journal-title":"HPB (Oxford)"},{"key":"ref479","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s11605-008-0553-4","article-title":"Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma","volume":"12","author":"M Abu-Hilal","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"ref480","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jso.21745","article-title":"Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection","volume":"104","author":"H Tashiro","year":"2011","journal-title":"J Surg Oncol"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3348\/kjr.2013.14.4.626","article-title":"Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection","volume":"14","author":"J W Kim","year":"2013","journal-title":"Korean J Radiol"},{"key":"ref482","doi-asserted-by":"crossref","first-page":"e3754","DOI":"10.1097\/MD.0000000000003754","article-title":"Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study","volume":"95","author":"C Tang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref483","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s12094-016-1611-0","article-title":"Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study","volume":"19","author":"A K Bholee","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"ref484","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.7150\/jca.19964","article-title":"Comparison of Combined Transcatheter Arterial Chemoembolization and CT-guided Radiofrequency Ablation with Surgical Resection in Patients with Hepatocellular Carcinoma within the Up-to-seven Criteria: A Multicenter Case-matched Study","volume":"8","author":"T Pan","year":"2017","journal-title":"J Cancer"},{"key":"ref485","first-page":"219","article-title":"Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma","volume":"24","author":"R Zhang","year":"2018","journal-title":"Diagn Interv Radiol"},{"key":"ref486","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0016-5085(88)90436-2","article-title":"Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial","volume":"94","author":"D Y Lin","year":"1988","journal-title":"Gastroenterology"},{"key":"ref487","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0168-8278(90)90110-D","article-title":"A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma","volume":"11","author":"G Pelletier","year":"1990","journal-title":"J Hepatol"},{"key":"ref488","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199505113321903","article-title":"A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma","volume":"332","year":"1995","journal-title":"N Engl J Med"},{"key":"ref489","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.510270617","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution","volume":"27","author":"J Bruix","year":"1998","journal-title":"Hepatology"},{"key":"ref490","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(98)80187-6","article-title":"Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial","volume":"29","author":"G Pelletier","year":"1998","journal-title":"Groupe CHC. J Hepatol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/1097-0142(19950515)75:10<2427::AID-CNCR2820751007>3.0.CO;2-J","article-title":"Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience","volume":"75","author":"G F Stefanini","year":"1995","journal-title":"Cancer"},{"key":"ref492","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/1097-0142(19940701)74:1<16::AID-CNCR2820740105>3.0.CO;2-V","article-title":"Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients","volume":"74","author":"J P Bronowicki","year":"1994","journal-title":"Cancer"},{"key":"ref493","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1365-2036.2009.04016.x","article-title":"Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis","volume":"29","author":"J H Kim","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"ref494","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/s00270-007-9032-7","article-title":"Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma","volume":"30","author":"S Herber","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref495","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1148\/radiol.10101058","article-title":"Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival","volume":"258","author":"G E Chung","year":"2011","journal-title":"Radiology"},{"key":"ref496","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/01.RVI.0000182185.47500.7A","article-title":"Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis","volume":"16","author":"C S Georgiades","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"ref497","first-page":"535","article-title":"Transcatheter arterial embolization for inoperable hepatocellular carcinoma","volume":"36","author":"M Okazaki","year":"1991","journal-title":"Jpn J Clin Radiol"},{"key":"ref498","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jvir.2011.07.002","article-title":"Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma","volume":"22","author":"R Sacco","year":"2011","journal-title":"J Vasc Interv Radiol"},{"key":"ref499","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000329602","article-title":"A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma","volume":"34","author":"H van Malenstein","year":"2011","journal-title":"Onkologie"},{"key":"ref500","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jso.21522","article-title":"Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)","volume":"101","author":"R Dhanasekaran","year":"2010","journal-title":"J Surg Oncol"},{"key":"ref501","first-page":"246","article-title":"[Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]","volume":"53","author":"M D Ferrer Puchol","year":"2011","journal-title":"Radiologia"},{"key":"ref502","doi-asserted-by":"crossref","first-page":"Cr189","DOI":"10.12659\/MSM.881714","article-title":"Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin\/lipiodol (cTACE)","volume":"17","author":"P Wiggermann","year":"2011","journal-title":"Med Sci Monit"},{"key":"ref503","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jhep.2012.07.017","article-title":"Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma","volume":"57","author":"M J Song","year":"2012","journal-title":"J Hepatol"},{"key":"ref504","first-page":"496","article-title":"Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs","volume":"57","author":"J E Meg\u00edas Vericat","year":"2015","journal-title":"Radiologia"},{"key":"ref505","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12885-015-1480-x","article-title":"Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma","volume":"15","author":"R Kloeckner","year":"2015","journal-title":"BMC Cancer"},{"key":"ref506","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jgh.13147","article-title":"Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma","volume":"31","author":"A Facciorusso","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"ref507","first-page":"69","article-title":"Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma","volume":"8","author":"J Baur","year":"2016","journal-title":"Hepat Med"},{"key":"ref508","first-page":"813","article-title":"Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis","volume":"60","author":"S Gao","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"ref509","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/jgh.12439","article-title":"Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma","volume":"29","author":"K Huang","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"ref510","first-page":"3892","article-title":"Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis","volume":"7","author":"X Zhou","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/1751-2980.12380","article-title":"Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis","volume":"17","author":"J H Zou","year":"2016","journal-title":"J Dig Dis"},{"key":"ref512","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.dld.2016.02.005","article-title":"Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis","volume":"48","author":"A Facciorusso","year":"2016","journal-title":"Dig Liver Dis"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1589-7568.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T05:35:13Z","timestamp":1764048913000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1589-7568"}},"subtitle":["Langversion 2.0 \u2013 Juni 2021, AWMF-Registernummer: 032-053OL"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":505,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2022,1,18]]},"published-print":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1589-7568","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}